Guidelines published by the Society of Interventional Radiology in 2010 primarily address percutaneous nephrostomy placement, exchange, and ureteral stents, although recommendations may potentially be extrapolated to suprapubic catheter placement or exchange. For these urinary interventions, the authors generally recommend antibiotic prophylaxis for initial placement, whereas routine exchange does not warrant prophylaxis in uninfected, unobstructed, immunocompetent patients. Factors predisposing to infection include advanced age, diabetes, bladder dysfunction, an indwelling catheter, previous urinary tract manipulation, ureterointestinal anastomosis, bacteriuria, and stones; patients with these risk factors should receive an appropriate antibiotic before intervention. The guideline identifies no preferred regimen but lists intravenous cefazolin 1 g, ceftriaxone 1 g, ampicillin/sulbactam 1.5–3 g, or ampicillin 2 g plus gentamicin 1.5 mg/kg as common options. When clinical infection is present, antibiotics constitute treatment rather than prophylaxis, with ongoing therapy tailored to urine culture results and continued until obstruction is relieved when applicable. These recommendations are supported primarily by limited observational evidence and expert guidance, rather than studies specifically evaluating suprapubic catheters. [1]
The 2019 Infectious Disease Society of America (IDSA) guideline recommends against screening for or treating asymptomatic bacteriuria (ASB) in patients with short-term (<30 days) or long-term indwelling urethral catheters (Strong recommendation, low-quality evidence) and states that similar management is reasonable for patients with suprapubic catheters. In contrast, patients undergoing endoscopic urologic procedures associated with mucosal trauma should be screened for and treated for ASB before surgery because bacteriuria in this setting poses a substantial risk of postoperative sepsis (Strong recommendation, moderate-quality evidence). For endoscopic urologic procedures, the guideline suggests obtaining a preprocedural urine culture and prescribing targeted rather than empiric antimicrobial therapy; for patients with ASB undergoing a urologic procedure, it suggests 1 to 2 doses initiated 30 to 60 minutes before the procedure. Diabetes and spinal cord injury are not indications to screen for or treat ASB, although urinary tract infection symptoms may be atypical in patients with spinal cord injury. The guideline does not specifically address antibiotic prophylaxis for interventional radiology-guided suprapubic catheter placement or routine exchange, provide procedure-specific risk factors, or identify a preferred antibiotic for these procedures. [2]
Additionally, the 2009 Infectious Diseases Society of America guideline for urinary catheterization, including suprapubic catheters, recommends against routine prophylactic antibiotics at catheter placement to prevent catheter-associated urinary tract infection (A-I), or at catheter replacement to prevent catheter-associated bacteriuria (A-III), citing antimicrobial resistance concerns and insufficient evidence that prophylaxis prevents bacteremia. Screening for and treating asymptomatic bacteriuria are also discouraged in catheterized patients, except during pregnancy or before urologic procedures in which visible mucosal bleeding is anticipated (A-III). Although granulocytopenia, urologic or gynecologic surgery, and surgery involving an implanted foreign body are discussed as potential circumstances for considering prophylaxis, the authors emphasize that these groups have not been studied and provide no established prophylaxis recommendation for them. Older age, diabetes, prolonged catheterization, and elevated serum creatinine are associated with bacteriuria but are not identified as independent indications for antibiotics. When symptomatic catheter-associated infection is present, urine culture should precede antibiotic treatment; if the catheter has been present for more than 2 weeks and remains necessary, replacement is recommended (A-I), with culture obtained from the newly placed catheter (A-II). [3]
The 2013 ASHP/IDSA/SIS/SHEA clinical practice guidelines for antimicrobial prophylaxis in surgery recommend no antimicrobial prophylaxis for clean urologic procedures in patients without risk factors for postoperative infection. For lower urinary tract instrumentation in patients with infection risk factors, recommended agents include a fluoroquinolone, trimethoprim–sulfamethoxazole, or cefazolin; for clean urologic procedures involving entry into the urinary tract, cefazolin is recommended. Urologic-specific risk factors include urinary tract anatomic abnormalities, urinary obstruction, urinary stones, and indwelling or externalized catheters; preoperative urinary tract infection, particularly recurrent infection, is identified as a high-risk factor. Additional procedure-specific risk factors include the duration of postoperative catheterization, irrigation mode, and postoperative pyuria. Patients with preoperative bacteriuria or urinary tract infection should be treated before the procedure when possible. The guidelines support short prophylactic courses consisting of a single dose or less than 24 hours and state that the literature does not support continuing prophylaxis until urinary catheters are removed. However, they do not provide specific recommendations for IR-guided suprapubic catheter placement or exchange. [4]
A 2010 narrative review describes a two-tiered antibiotic approach for urinary tract procedures such as suprapubic cystostomy, citing a 9% rate of postprocedural sepsis. For uncomplicated patients, the authors describe a one-time dose of a first-generation cephalosporin or gentamicin as appropriate; for high-risk patients or those presenting with signs of infection, they recommend ampicillin-sulbactam, ampicillin plus gentamicin, or a cephalosporin plus gentamicin. In the discussion of percutaneous nephrostomy, risk factors for infectious complications include advanced age, immunosuppression, diabetes, stone disease, ureterointestinal conduits, renal insufficiency, voiding dysfunction, and previous instrumentation with suboptimal drainage. For routine nephrostomy catheter exchanges, the authors describe a lower risk of sepsis and note that some practitioners omit prophylaxis, whereas intravenous antibiotics may be particularly useful when the catheter is malpositioned or malfunctioning. The review does not provide separate recommendations for suprapubic catheter exchanges or explicitly identify circumstances in which prophylaxis should be omitted for suprapubic catheter placement. [5]
Literature discussing percutaneous nephrostomy and ureteral interventions support a risk-based approach to antibiotic prophylaxis, with benefit demonstrated primarily in high-risk patients and no statistically significant benefit established in low-risk patients. Infection risk factors include advanced age, diabetes, neurogenic bladder or bladder dysfunction, indwelling urinary catheters, previous urinary tract manipulation, ureterointestinal anastomosis, bacteriuria, and urinary stones; pyuria and hydronephrosis are also associated with febrile infectious complications. For routine nephrostomy exchanges, prophylaxis is recommended for high-risk patients, particularly those with ureteral stents, ureteroileal anastomosis, or indwelling urinary catheters, and for patients with catheter occlusion. Clinically relevant infection remains uncommon with a functioning, unobstructed nephrostomy despite bacterial colonization. Antibiotic coverage targets Escherichia coli, Proteus, Klebsiella, and Enterococcus, with reported regimens including intravenous ceftriaxone 1–2 g, ampicillin/sulbactam, or ampicillin plus gentamicin. Established infection or sepsis requires antibiotic treatment rather than prophylaxis, initially empiric and subsequently directed by the identified organism; treatment is continued until obstruction is relieved when applicable. [6], [7], [8]